Literature DB >> 25275822

Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material.

Eduard Ayuso1, Véronique Blouin, Martin Lock, Susan McGorray, Xavier Leon, Mauricio R Alvira, Alberto Auricchio, Stephanie Bucher, Abdelwahed Chtarto, K Reed Clark, Christophe Darmon, Monica Doria, Will Fountain, Guangping Gao, Kai Gao, Mauro Giacca, Juergen Kleinschmidt, Barbara Leuchs, Catherine Melas, Hiroaki Mizukami, Marcus Müller, Yvet Noordman, Olivier Bockstael, Keiya Ozawa, Catherine Pythoud, Marina Sumaroka, Richard Surosky, Liliane Tenenbaum, Inge van der Linden, Brigitte Weins, J Fraser Wright, Xinhua Zhang, Lorena Zentilin, Fatima Bosch, Richard O Snyder, Philippe Moullier.   

Abstract

Abstract Gene therapy approaches using recombinant adeno-associated virus serotype 2 (rAAV2) and serotype 8 (rAAV8) have achieved significant clinical benefits. The generation of rAAV Reference Standard Materials (RSM) is key to providing points of reference for particle titer, vector genome titer, and infectious titer for gene transfer vectors. Following the example of the rAAV2RSM, here we have generated and characterized a novel RSM based on rAAV serotype 8. The rAAV8RSM was produced using transient transfection, and the purification was based on density gradient ultracentrifugation. The rAAV8RSM was distributed for characterization along with standard assay protocols to 16 laboratories worldwide. Mean titers and 95% confidence intervals were determined for capsid particles (mean, 5.50×10(11) pt/ml; CI, 4.26×10(11) to 6.75×10(11) pt/ml), vector genomes (mean, 5.75×10(11) vg/ml; CI, 3.05×10(11) to 1.09×10(12) vg/ml), and infectious units (mean, 1.26×10(9) IU/ml; CI, 6.46×10(8) to 2.51×10(9) IU/ml). Notably, there was a significant degree of variation between institutions for each assay despite the relatively tight correlation of assay results within an institution. This outcome emphasizes the need to use RSMs to calibrate the titers of rAAV vectors in preclinical and clinical studies at a time when the field is maturing rapidly. The rAAV8RSM has been deposited at the American Type Culture Collection (VR-1816) and is available to the scientific community.

Entities:  

Mesh:

Year:  2014        PMID: 25275822      PMCID: PMC4236062          DOI: 10.1089/hum.2014.057

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  28 in total

1.  Herpesvirus-based infectious titering of recombinant adeno-associated viral vectors.

Authors:  Imran Mohiuddin; Scott Loiler; Irina Zolotukhin; Barry J Byrne; Terence R Flotte; Richard O Snyder
Journal:  Mol Ther       Date:  2005-02       Impact factor: 11.454

2.  Development of AAV serotype-specific ELISAs using novel monoclonal antibodies.

Authors:  Dirk Kuck; Andrea Kern; Jürgen A Kleinschmidt
Journal:  J Virol Methods       Date:  2006-11-28       Impact factor: 2.014

3.  Proteolytic mapping of the adeno-associated virus capsid.

Authors:  Kim Van Vliet; Veronique Blouin; Mavis Agbandje-McKenna; Richard O Snyder
Journal:  Mol Ther       Date:  2006-09-27       Impact factor: 11.454

4.  International efforts for recombinant adeno-associated viral vector reference standards.

Authors:  Philippe Moullier; Richard O Snyder
Journal:  Mol Ther       Date:  2008-07       Impact factor: 11.454

5.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.

Authors:  Corinna Burger; Oleg S Gorbatyuk; Margaret J Velardo; Carmen S Peden; Philip Williams; Sergei Zolotukhin; Paul J Reier; Ronald J Mandel; Nicholas Muzyczka
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

6.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

7.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

8.  CD8(+) T-cell responses to adeno-associated virus capsid in humans.

Authors:  Federico Mingozzi; Marcela V Maus; Daniel J Hui; Denise E Sabatino; Samuel L Murphy; John E J Rasko; Margaret V Ragni; Catherine S Manno; Jurg Sommer; Haiyan Jiang; Glenn F Pierce; Hildegund C J Ertl; Katherine A High
Journal:  Nat Med       Date:  2007-03-18       Impact factor: 53.440

9.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

10.  Clades of Adeno-associated viruses are widely disseminated in human tissues.

Authors:  Guangping Gao; Luk H Vandenberghe; Mauricio R Alvira; You Lu; Roberto Calcedo; Xiangyang Zhou; James M Wilson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more
  28 in total

1.  Quantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes.

Authors:  Jian Xu; Steven H DeVries; Yongling Zhu
Journal:  Hum Gene Ther       Date:  2020-07-14       Impact factor: 5.695

2.  AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations.

Authors:  Simon Pacouret; Mohammed Bouzelha; Rajani Shelke; Eva Andres-Mateos; Ru Xiao; Anna Maurer; Mathieu Mevel; Heikki Turunen; Trisha Barungi; Magalie Penaud-Budloo; Frédéric Broucque; Véronique Blouin; Philippe Moullier; Eduard Ayuso; Luk H Vandenberghe
Journal:  Mol Ther       Date:  2017-04-17       Impact factor: 11.454

3.  Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract.

Authors:  F Kurosaki; R Uchibori; N Mato; Y Sehara; Y Saga; M Urabe; H Mizukami; Y Sugiyama; A Kume
Journal:  Gene Ther       Date:  2017-03-27       Impact factor: 5.250

4.  Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A.

Authors:  William Lostal; Carinne Roudaut; Marine Faivre; Karine Charton; Laurence Suel; Nathalie Bourg; Heather Best; John Edward Smith; Jochen Gohlke; Guillaume Corre; Xidan Li; Zaher Elbeck; Ralph Knöll; Jack-Yves Deschamps; Henk Granzier; Isabelle Richard
Journal:  Sci Transl Med       Date:  2019-11-27       Impact factor: 17.956

5.  Synthetic certified DNA reference material for analysis of human erythropoietin transgene and transcript in gene doping and gene therapy.

Authors:  A Baoutina; S Bhat; M Zheng; L Partis; M Dobeson; I E Alexander; K R Emslie
Journal:  Gene Ther       Date:  2016-06-07       Impact factor: 5.250

6.  Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.

Authors:  Annette Von Drygalski; Adam Giermasz; Giancarlo Castaman; Nigel S Key; Susan Lattimore; Frank W G Leebeek; Wolfgang Miesbach; Michael Recht; Alison Long; Robert Gut; Eileen K Sawyer; Steven W Pipe
Journal:  Blood Adv       Date:  2019-11-12

Review 7.  Gene therapy in an era of emerging treatment options for hemophilia B.

Authors:  P E Monahan
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

8.  Reply to "Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors".

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-11-11       Impact factor: 11.454

9.  Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-09-09       Impact factor: 11.454

10.  Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.

Authors:  Christian Hinderer; Nathan Katz; Elizabeth L Buza; Cecilia Dyer; Tamara Goode; Peter Bell; Laura K Richman; James M Wilson
Journal:  Hum Gene Ther       Date:  2018-02-12       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.